ABVC BioPharma, Inc. (NASDAQ: ABVC) announced it has received a licensing payment of US$145,950 from partner OncoX BioPharma, Inc., bringing total OncoX payments in the third quarter of 2025 to nearly US$600,000. Combined with revenues from AiBtl BioPharma and ForSeeCon Eye Corporation, the company’s total consolidated licensing revenues for the quarter to date stand at US$1,275,950, highlighting a high-margin revenue stream that carries minimal incremental costs.
The latest payment from OncoX comes under the global licensing agreement between the two companies. ABVC has licensed four IND-approved oncology assets to OncoX, and OncoX is pursuing additional acquisitions, including the Lycogen® lycopene platform, to expand its portfolio. According to ABVC’s CEO, Dr. Uttam Patil, these milestone revenues directly contribute to enhancing ABVC’s profitability profile. “This US$145,950 licensing payment from OncoX brings our total OncoX receipts in Q3 to nearly US$600,000 and underscores the current strength and reliability of our licensing framework,” Patil said.
ABVC’s licensing model allows it to generate revenue without incurring significant additional development costs, as most expenses were incurred in prior years. The company has an active pipeline of six drugs and one medical device, Vitargus®, developed in collaboration with research institutions such as Stanford University and the University of California at San Francisco. For Vitargus®, ABVC plans to conduct pivotal Phase III trials through global partnerships.
OncoX BioPharma, a clinical-stage company focused on cancer immunotherapies from natural sources, has three proprietary pipeline programs and four FDA-approved INDs. It is also expanding into cancer-supportive care and preventative health via natural ingredients, with the Lycogen® platform targeting markets in preventative medicine, chronic disease, and aesthetic medicine. Allied Market Research projects the global lycopene market to reach $187 million by 2030, according to a press release.
OncoX operates under a strategic collaboration with BioKey Inc., a U.S. FDA-registered facility, and plans to expand into the United States, Japan, Taiwan, and other Asia-Pacific markets. The total potential deal proceeds from OncoX, including milestone payments and private equity, are valued at up to US$105 million, though there is no guarantee all milestones will be achieved.
The strong licensing revenue reported by ABVC reflects the viability of its asset-light strategy, which leverages prior R&D investments to generate recurring income. As the company continues to advance its pipeline and secure partnerships, it aims to strengthen its cash position and long-term growth prospects.
